News By Tag
News By Place
Follow on Google News
SCA Robotics Joins NVIDIA Inception Program
By: SCA Robotics
SCA Robotics is a core technology company building AI medical solutions related to the diagnostics of cancer and other chronic diseases. As a strategic partner to the world-renowned City of Hope Comprehensive Cancer Center in Los Angeles, SCA pioneered the first AI solution related to metastatic and nonmetastatic tumor identification within the brain. SCA has experience working on various AI projects related to diabetes, interventional heart disease, T-cell intervention, and eye disease.
The NVIDIA Inception program provides SCA Robotics with a platform and infrastructure to build cutting-edge computer vision applications as they relate to medicine and other industries. The program assists emerging AI companies, such as SCA Robotics, with the latest AI tools, technology, and deep learning expertise, which are critically needed resources.
SCA Robotics CEO Rob Rao commented, "Thanks to NVIDIA's tools and resources, the unification of SCA's AI algorithms with cutting-edge GPU hardware will usher in a paradigm shift in medicine that will revolutionize the way medical care is provided."
NVIDIA's Inception program is a virtual accelerator program that helps startups during critical stages of product development, prototyping, and deployment. Every Inception member gets a custom set of ongoing benefits, from hardware grants and marketing support to training with deep learning experts.
About SCA Robotics
SCA Robotics is a high-performing team of computer vision and data analytics experts building Artificial Intelligence medical solutions relating to the diagnostics of cancer and other chronic diseases. As a strategic partner to the world-renowned City of Hope Comprehensive Cancer Center in Los Angeles, SCA pioneered the first AI solution related to metastatic and nonmetastatic tumor identification within the brain. In addition to the COH partnership, SCA has experience with AI projects relating to diabetes, interventional heart disease, T cell intervention, and vision loss prevention (eye disease). SCA was selected and attended the prestigious American Diabetes Association's 23rd Annual Leaders Forum Healthtech Showcase for its work in AI and diabetes.
For additional information or to request a presentation visit:
Max Wasilko, VP of Business Development